Research

Area 5

Physiopathology and molecular bases in hematology

Team leader

Strategic objectives

  • Identification of potential points of intervention and development of new therapeutic strategies and combination approaches based on the genetic and molecular mechanisms implicated in the development and progression of lymphoid malignancies, with the idea to translate bench-to-bedside. Our aim is to perform a personalized therapy based on the optimization of treatment for each patient, improving the benefits and avoiding the negative side effects.
  • To improve the diagnosis of lymphoid malignancies using histopathological, immunophenotypic and molecular biology technologies.
  • To increase the efficacy of diagnosis, treatment and follow up of patients with rare anemias to improve their quality of life.

Main lines of research

  1. To analyze the functionality and the therapeutic applicability of target drugs against recurrent alterations in chronic lymphocytic leukemia (CLL), when specific inhibitors are available.
  2. Characterization of molecular pathways activated by microenvironment in follicular lymphoma (FL) and mantle cell lymphoma (MCL) and CLL as a discovery tool of new therapeutic targets and resistance to treatments.
  3. New targeted therapies against oncogenes and microenvironment in diffuse large B cell lymphomas (DLBCL).
  4. Cytological, immunophenotypic and molecular study of malignant hematological diseases. Development of new technologies for the diagnosis and follow-up of minimum residual disease (MRD).
  5. Promotion of cooperative strategies in the molecular diagnostic setting of leukemias and lymphomas.
  6. Design and implementation of internal and external quality control programs.
  7. Cutaneous T and B cell lymphomas. Clinical, histopathological and immunophenotypic study. Prognostic factors and epidemiology.
  8. Molecular study of the congenital defects of erythrocytes and erythropoiesis, rare anaemias, and physiopathological mechanisms intervening in the production and senescence of red blood cells as a cause of anemia or erythrocytosis.
  9. Genetic and epidemiological study of hemoglobinopathies,and thalassemias. Development of technologies for the newborn screening of sickle-cell disease (SCD).
  10. Investigation of Red Blood Cells (RBC) membrane structure and function. Ion transport mechanisms and RBC osmotic deformability measurements with the LORCCA.
  11. Investigation of etiological mechanisms of very rare anaemias with unknown aetiology by New Generation Sequencing (NGS).